Enhancing Hematological Resilience to Chemotherapy through Synthesit® in Advanced Oral Cavity Cancer: A Case Report

Background: Anemia and myelosuppression due to chemotherapy are frequent side effects that may require treatment. This case examines the effect of Synthesit® (ferric iron III citrate) and its bioavailable iron components on hematologic recovery and general stability during the course of chemotherapy in a patient with stage III cancer of the oral cavity. Case Presentation: Patient M., a 53-year-old woman diagnosed with stage III oral cavity cancer (T3N2M0), experienced severe hematologic toxicity, including anemia and leukopenia, after three cycles of CF chemotherapy. The treatment was interrupted due to deteriorating blood parameters. Following the introduction of Synthesit® and Sorbifer, along with continued chemotherapy, the blood parameters improved, and treatment resumed. The patient’s condition stabilized with reintroduction of Synthesit®. Aims: This study focused on the evaluation of Synthesit® as an adjunctive agent in the management of stage III oral cavity cancer with particular emphasis on hematologic recovery, patient stability, and chemotherapy tolerance. Methods: A single-case study with a longitudinal observational design was conducted using laboratory results, chemotherapy logs, and medical records. Hematological parameters such as RBC, Hb, WBC, and PLT were monitored across chemotherapy phases, including Synthesit® and Sorbifer administration. Results: The introduction of Synthesit® and Sorbifer improved hematologic parameters. RBC count increased from 3.53 T/L to 3.88 T/L, and hemoglobin levels rose from 10.2 g/dL to 10.5 g/dL, indicating a partial recovery in erythropoiesis. Despite this, the white blood cell count decreased significantly to 2.91 G/L, highlighting ongoing myelosuppression. The patient showed a positive response in the red blood parameters, although the immune function remained compromised. Neutrophil levels significantly decreased, from 12.03 G/L to 1.41 G/L, suggesting chemotherapy-induced myelosuppression. Eosinophils and basophils remained stable, whereas lymphocytes showed a slight increase, possibly indicating an immune response. Conclusion: Synthesit® increases the levels of hemoglobin, erythrocytes, and hematocrit, thus improving hematologic recovery during chemotherapy. It proposes continued treatment, which indicates its possible effectiveness as an adjunct treatment for chemotherapy-related anemia.